We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
-8.28%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$15.7M
AUM Growth
-$3.42M
(-18%)
Cap. Flow
-$141K
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
72.96%
Holding
21
New
2
Increased
2
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jasper Therapeutics
JSPR
|
+$762K |
| 2 |
MRSN
Mersana Therapeutics
MRSN
|
+$397K |
| 3 |
Humacyte
HUMA
|
+$313K |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$291K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$948K |
| 2 |
BridgeBio Pharma
BBIO
|
+$482K |
| 3 |
Insmed
INSM
|
+$474K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$23.4B
| $2.33M | 14.84% |
30,500
-6,200
| -17% | -$474K |
|
2
Ardelyx
ARDX
$1.26B
| $1.65M | 10.51% |
335,400
| – | – |
|
3
Mineralys Therapeutics
MLYS
$2.38B
| $1.25M | 8% |
79,000
| – | – |
|
4
Fennec Pharmaceuticals
FENC
$356M
| $1.19M | 7.6% |
195,700
| – | – |
|
5
Kiniksa Pharmaceuticals
KNSA
$4.87B
| $1.02M | 6.5% |
45,900
| – | – |
|
|
6
BridgeBio Pharma
BBIO
$16.2B
| $899K | 5.73% |
26,000
-14,300
| -35% | -$482K |
|
7
Benitec Biopharma
BNTC
$393M
| $807K | 5.15% |
62,000
| – | – |
|
8
Geron
GERN
$930M
| $795K | 5.07% |
500,000
| – | – |
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $773K | 4.93% |
98,700
+34,700
| +54% | +$291K |
|
10
Arcutis Biotherapeutics
ARQT
$3.41B
| $724K | 4.62% |
46,300
| – | – |
|
11
Syndax Pharmaceuticals
SNDX
$1.87B
| $676K | 4.31% |
55,000
| – | – |
|
|
12
Jasper Therapeutics
JSPR
$23.5M
| $630K | 4.02% |
146,500
+114,500
| +358% | +$762K |
|
13
Biohaven
BHVN
$2.19B
| $546K | 3.48% |
22,700
| – | – |
|
14
Disc Medicine
IRON
$2.88B
| $526K | 3.36% |
10,600
| – | – |
|
|
15
Milestone Pharmaceuticals
MIST
$148M
| $439K | 2.8% |
548,806
-477,000
| -47% | -$948K |
|
16
Regenxbio
RGNX
$650M
| $413K | 2.63% |
57,750
| – | – |
|
|
BLUE
17
DELISTED
bluebird bio
BLUE
| $385K | 2.46% |
78,912
| – | – |
|
18
Seres Therapeutics
MCRB
$50.8M
| $239K | 1.52% |
17,038
| – | – |
|
|
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
| $222K | 1.41% |
+25,760
| New | +$397K |
|
|
20
Humacyte
HUMA
$172M
| $142K | 0.91% |
+83,500
| New | +$313K |
|
|
SPRB
21
Spruce Biosciences
SPRB
$122M
| $21.8K | 0.14% |
1,000
| – | – |
|
Similar funds
PA
PA
SR
SCTC
SRA
CP
B
CVV
Lion Point Capital's Q1 2025 Portfolio in Review
As of Q1 2025, Lion Point Capital held 21 positions worth $15.7M, down 18% from $19.1M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Lion Point Capital's Q1 2025 filing shows 2 new, 2 increased and 3 reduced positions. Its largest new stake was Mersana Therapeutics: 25,760 shares worth $222K. The largest sale was Milestone Pharmaceuticals, an estimated $948K.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Lion Point Capital's largest Q1 2025 buy was Mersana Therapeutics: 25,760 shares worth $222K.
- Lion Point Capital added most to Jasper Therapeutics in Q1 2025, an estimated $762K increase.
- Lion Point Capital's biggest Q1 2025 reduction was Milestone Pharmaceuticals, cutting an estimated $948K.
- Lion Point Capital's ten largest holdings make up 73% of its $15.7M portfolio in Q1 2025.
- Lion Point Capital opened 2 new positions and closed 0 in Q1 2025.
- Lion Point Capital's portfolio value fell 18% quarter-over-quarter to $15.7M.
Based on Lion Point Capital's 13F filing for Q1 2025, filed 15 May 2025.